` HLUN A (H Lundbeck A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

HLUN A
vs
OMX Copenhagen 25

Over the past 12 months, HLUN A has outperformed OMX Copenhagen 25, delivering a return of -7% compared to the OMX Copenhagen 25's 12% drop.

Stocks Performance
HLUN A vs OMX Copenhagen 25

Loading

Performance Gap
HLUN A vs OMX Copenhagen 25

Loading
HLUN A
OMX Copenhagen 25
Difference

Performance By Year
HLUN A vs OMX Copenhagen 25

Loading
HLUN A
OMX Copenhagen 25
Add Stock

Competitors Performance
H Lundbeck A/S vs Peers

OMX Copenhagen 25
HLUN A
LLY
JNJ
NOVO B
ROG
Add Stock

H Lundbeck A/S
Glance View

Market Cap
30.1B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
55.84 DKK
Undervaluation 46%
Intrinsic Value
Price
Back to Top